This document is an excerpt from the EUR-Lex website
Document 22017D1301
Decision of the EEA Joint Committee No 18/2016 of 5 February 2016 amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2017/1301]
Decision of the EEA Joint Committee No 18/2016 of 5 February 2016 amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2017/1301]
Decision of the EEA Joint Committee No 18/2016 of 5 February 2016 amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2017/1301]
OJ L 189, 20.7.2017, pp. 25–26
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
In force
|
20.7.2017 |
EN |
Official Journal of the European Union |
L 189/25 |
DECISION OF THE EEA JOINT COMMITTEE
No 18/2016
of 5 February 2016
amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2017/1301]
THE EEA JOINT COMMITTEE,
Having regard to the Agreement on the European Economic Area (‘the EEA Agreement’), and in particular Article 98 thereof,
Whereas:
|
(1) |
Commission Implementing Regulation (EU) 2015/1981 of 4 November 2015 approving Formaldehyde released from N,N-Methylenebismorpholine as an existing active substance for use in biocidal products for product-types 6 and 13 (1) is to be incorporated into the EEA Agreement. |
|
(2) |
Commission Implementing Regulation (EU) 2015/1982 of 4 November 2015 approving hexaflumuron as an existing active substance for use in biocidal products for product-type 18 (2) is to be incorporated into the EEA Agreement. |
|
(3) |
Commission Implementing Decision (EU) 2015/1985 of 4 November 2015 pursuant to Article 3(3) of Regulation (EU) No 528/2012 of the European Parliament and of the Council on an anti-viral tissue impregnated with citric acid (3) is to be incorporated into the EEA Agreement. |
|
(4) |
Annex II to the EEA Agreement should therefore be amended accordingly, |
HAS ADOPTED THIS DECISION:
Article 1
The following points are inserted after point 12nns (Commission Implementing Regulation (EU) 2015/1759) of Chapter XV of Annex II to the EEA Agreement:
|
‘12nnt. |
32015 R 1981: Commission Implementing Regulation (EU) 2015/1981 of 4 November 2015 approving Formaldehyde released from N,N-Methylenebismorpholine as an existing active substance for use in biocidal products for product-types 6 and 13 (OJ L 289, 5.11.2015, p. 9). |
|
12nnu. |
32015 R 1982: Commission Implementing Regulation (EU) 2015/1982 of 4 November 2015 approving hexaflumuron as an existing active substance for use in biocidal products for product-type 18 (OJ L 289, 5.11.2015, p. 13). |
|
12nnv. |
32015 D 1985: Commission Implementing Decision (EU) 2015/1985 of 4 November 2015 pursuant to Article 3(3) of Regulation (EU) No 528/2012 of the European Parliament and of the Council on an anti-viral tissue impregnated with citric acid (OJ L 289, 5.11.2015, p. 26).’ |
Article 2
The texts of Implementing Regulations (EU) 2015/1981 and (EU) 2015/1982 and Implementing Decision (EU) 2015/1985 in the Icelandic and Norwegian languages, to be published in the EEA Supplement to the Official Journal of the European Union, shall be authentic.
Article 3
This Decision shall enter into force on 6 February 2016, provided that all the notifications under Article 103(1) of the EEA Agreement have been made (*1).
Article 4
This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the Official Journal of the European Union.
Done at Brussels, 5 February 2016.
For the EEA Joint Committee
The President
Claude MAERTEN
(1) OJ L 289, 5.11.2015, p. 9.
(2) OJ L 289, 5.11.2015, p. 13.
(3) OJ L 289, 5.11.2015, p. 26.
(*1) No constitutional requirements indicated.